{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T02:13:55Z","timestamp":1783649635558,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":52,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-026-04925-3","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T01:34:47Z","timestamp":1779154487000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical real-world data evaluation: comparison of central macular thickness after anti-VEGF treatment in diabetic macular edema patients treated with or without topical anti-glaucoma agents"],"prefix":"10.1186","volume":"26","author":[{"given":"Hakan","family":"Baybora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ece","family":"\u00d6zal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sad\u0131k Altan","family":"\u00d6zal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"4925_CR1","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11892-019-1188-4","volume":"19","author":"EJ Kim","year":"2019","unstructured":"Kim EJ, Lin WV, Rodriguez SM, et al. Treatment of diabetic macular edema. Curr Diab Rep. 2019;19:68.","journal-title":"Curr Diab Rep"},{"issue":"2","key":"4925_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IIO.0b013e31819fd164","volume":"49","author":"A Singh","year":"2009","unstructured":"Singh A, Stewart JM. Pathophysiology of diabetic macular edema. Int Ophthalmol Clin. 2009;49(2):1\u201311.","journal-title":"Int Ophthalmol Clin"},{"issue":"2","key":"4925_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S2213-8587(16)30052-3","volume":"5","author":"GS Tan","year":"2017","unstructured":"Tan GS, Cheung N, Sim\u00f3 R, Cheung GC, Wong TY. Diabetic macular oedema. Lancet Diabetes Endocrinol. 2017;5(2):143\u201355.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"4925_CR4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41433-021-01722-8","volume":"36","author":"M Iglicki","year":"2022","unstructured":"Iglicki M, Gonz\u00e1lez DP, Loewenstein A, Zur D. Next-generation anti-VEGF agents for diabetic macular oedema. Eye (Lond). 2022;36(2):273\u20137.","journal-title":"Eye (Lond)"},{"issue":"6","key":"4925_CR5","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1007\/s12325-017-0548-1","volume":"34","author":"N Dervenis","year":"2017","unstructured":"Dervenis N, Mikropoulou AM, Tranos P, Dervenis P. Ranibizumab in the treatment of diabetic macular edema: a review of the Current status, unmet needs, and emerging challenges. Adv Ther. 2017;34(6):1270\u201382.","journal-title":"Adv Ther"},{"issue":"2","key":"4925_CR6","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/eye.2015.217","volume":"30","author":"V Chong","year":"2016","unstructured":"Chong V. Ranibizumab for the treatment of wet AMD: A summary of real-world studies. Eye (Lond). 2016;30(2):270\u201386.","journal-title":"Eye (Lond)"},{"issue":"12","key":"4925_CR7","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1136\/bjophthalmol-2015-308166","volume":"100","author":"FG Holz","year":"2016","unstructured":"Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Hykin P, et al. Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. Br J Ophthalmol. 2016;100(12):1623\u20138.","journal-title":"Br J Ophthalmol"},{"key":"4925_CR8","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","volume":"372","author":"N Research","year":"2015","unstructured":"Diabetic Retinopathy Clinical, Research N, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193\u2013203.","journal-title":"N Engl J Med"},{"issue":"9","key":"4925_CR9","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaophthalmol.2023.2421","volume":"141","author":"CC Wycoff","year":"2023","unstructured":"Wycoff CC, Brown DM, Reed K, Berliner AJ, Gerstenbilth AT, Breazna AJ, et al. Effect of High- Dose Intravitreal Aflibercept, 8\u00a0mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial. JAMA Ophthalmol. 2023;141(9):834\u201342.","journal-title":"JAMA Ophthalmol"},{"key":"4925_CR10","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/pharmaceutics11080365","volume":"11","author":"L Garc\u00eda-Quintanilla","year":"2019","unstructured":"Garc\u00eda-Quintanilla L, Luaces-Rodr\u00edguez A, GilMart\u00ednez M, et al. Pharmacokinetics of intravitrealanti-VEGF drugs in age-related macular degeneration. Pharmaceutics. 2019;11:365.","journal-title":"Pharmaceutics"},{"issue":"2","key":"4925_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1167\/tvst.14.2.21","volume":"14","author":"S Inoda","year":"2025","unstructured":"Inoda S, Takahashi H, Takahashi R, Hashimoto Y, Yoshida H, Takahashi H, Fujino Y, Aizawa K, Kawashima H, Yanag Y. Effect of Combination Use of Aqueous Humor SecretionInhibitor Eye Drops on Aflibercept Level: A Preliminary Analysis. Transl Vis Sci Technol. 2025;14(2):21.","journal-title":"Transl Vis Sci Technol"},{"key":"4925_CR12","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Layana A, Figueroa MS, Arias L, Araiz J, Ruiz-Moreno JM, Garc\u00eda-Arum\u00ed J, G\u00f3mez-Ulla F, L\u00f3pez-G\u00e1lvez MI, Cabrera-L\u00f3pez F, Garc\u00eda-Campos JM, et al. Individualized therapy with ranibizumab in wet age-related macular degeneration. J. Ophthalmol. 2015;2015:412903.","DOI":"10.1155\/2015\/412903"},{"key":"4925_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jconrel.2013.01.018","volume":"167","author":"Q Xu","year":"2013","unstructured":"Xu Q, Boylan NJ, Suk JS, Wang Y-Y, Nance EA, Yang J-C, McDonnell PJ, Cone RA, Duh EJ, Hanes J. Nanoparticle diffusion in, and micro rheology of, the bovine vitreous ex vivo. J Control Release. 2013;167:76\u201384.","journal-title":"J Control Release"},{"key":"4925_CR14","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.preteyeres.2010.04.003","volume":"29","author":"A Laude","year":"2010","unstructured":"Laude A, Tan LE, Wilson CG, Lascaratos G, Elashry M, Aslam T, Patton N, Dhillon B. Intravitreal therapy for neovascular age-related macular degeneration and inter-individual variations in vitreous pharmacokinetics. Prog Retin Eye Res. 2010;29:466\u201375.","journal-title":"Prog Retin Eye Res"},{"key":"4925_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/IAE.0000000000000265","volume":"35","author":"TU Krohne","year":"2015","unstructured":"Krohne TU, Muether PS, Stratmann NK, Holz FG, Kirchhof B, Meyer CH, Fauser S. Influence of ocular volume and lens status on pharmacokinetics and duration of action of intravitreal vascular endothelial growth factor inhibitors. Retina. 2015;35:69\u201374.","journal-title":"Retina"},{"key":"4925_CR16","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ajo.2018.05.026","volume":"192","author":"M Okada","year":"2018","unstructured":"Okada M, Kandasamy R, Chong EW, McGuiness M, Guymer RH. The Treat-and-Extend Injection Regimen Versus Alternate Dosing Strategies in Age-related Macular Degeneration: A Systematic Review and Meta-analysis. Am J Ophthalmol. 2018;192:184\u201397.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"4925_CR17","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114(5):855\u20139.","journal-title":"Ophthalmology"},{"issue":"2","key":"4925_CR18","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.xphs.2024.12.005","volume":"114","author":"JM Chowdhury","year":"2025","unstructured":"Chowdhury JM, Chacin Ruiz EA, Ohr MP, Swindle-Reilly KE, Ford Versypt AN. Computer modeling of bevacizumab drug distribution after intravitreal injection in rabbit and human eyes. J Pharm Sci. 2025;114(2):1164\u201374.","journal-title":"J Pharm Sci"},{"issue":"1","key":"4925_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00417-008-0917-1","volume":"247","author":"SH Byeon","year":"2009","unstructured":"Byeon SH, Kwon OW, Song JH, Kim SE, Park YS. Prolongation of activity of single intravitreal bevacizumab by adjuvant topical aqueous depressant (Timolol-Dorzolamide). Graefes Arch Clin Exp Ophthalmol. 2009;247(1):35\u201342.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4925_CR20","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1167\/iovs.04-0601","volume":"46","author":"J Gaudreault","year":"2005","unstructured":"Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Investig Ophthalmol Vis Sci. 2005;46:726\u201333.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"4","key":"4925_CR21","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/eye.2014.329","volume":"29","author":"SJ Park","year":"2015","unstructured":"Park SJ, Oh J, Kim YK, Park JH, Park JY, Hong HK, Park KH, Lee JE, Kim HM, Chung JY, Woo SJ. Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-Trap in a rabbit model. Eye (Lond). 2015;29(4):561\u20138.","journal-title":"Eye (Lond)"},{"issue":"19","key":"4925_CR22","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.3390\/diagnostics15192539","volume":"15","author":"S Li","year":"2025","unstructured":"Li S, Li M, Sun A, Zhang H. Hyperreflective Dots on SD-OCT: Implications for Predicting Treatment Outcomes in Diabetic Macular Edema. Diagnostics. 2025;15(19):2539.","journal-title":"Diagnostics"},{"key":"4925_CR23","doi-asserted-by":"crossref","unstructured":"Sassalos MT, Paulus YM. Prefilled syringes for intravitreal drug delivery. Clin Ophthalmol. 2019;13:701\u2013706.","DOI":"10.2147\/OPTH.S169044"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-04925-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04925-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04925-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:52:24Z","timestamp":1783648344000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-04925-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4925"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-04925-3","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consents were obtained from all patients.Basaksehir Cam and Sakura City Hospital Ethics Committee was approved the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"2025\/283. The study adhered to the tenets of the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"IRB number"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"403"}}